DMK Pharmaceuticals (NASDAQ: DMK) (previously Adamis Pharma). is a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders.The commercially approved products include ZIMHI® (naloxone) and SYMJEPI®. ZIMHI® (naloxone) Injection is FDA approved for opioid overdose emergency rescue. SYMJEPI® (epinephrine) Injection is FDA approved for use in the emergency treatment of acute allergic reactions, including anaphylaxis. Show more

11682 El Camino Real Ste 300, California, 92130, US

www.adamispharmaceuticals.com

Pharmaceutical Preparation Manufacturing

Manufacturing

Start AI Chat

Market Cap

0.00

52 Wk Range

$0.23 - $0.23

Previous Close

$0.23

Open

$0.18

Volume

21,464,152

Day Range

$0.23 - $0.23

Enterprise Value

0.00

Cash

0.00

Avg Qtr Burn

N/A

Insider Ownership

9.26%

Institutional Own.

2.44%

Qtr Updated

06/30/24

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
SYMJEPI (epinephrine 0.3mg and 0.15mg) Details Anaphylaxis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZIMHI (naloxone 5mg) Details Opioid overdose	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DPI-221 Details Benign prostatic hyperplasia (BPH)	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DPI-125 Details Opioid use disorder	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
APC-400 (tempol) Details Radiation Dermatitis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
APC-410 (tempol) Details Acute respiratory distress syndrome, Inflammatory disease, COVID-19	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.